Virios Therapeutics

Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID

Retrieved on: 
Monday, February 28, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Center of excellence, Conditional sentence, Fibromyalgia, Long, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, Pain, Myalgia, Diagnosis, Immune system, Autoantibody, COVID-19, Therapy, Chronic fatigue syndrome, Company, Functional somatic syndrome, World, Center, Trial of the century, Celecoxib, FM, Food, DNA, Attention, Famciclovir, Valaciclovir, Sleep, Fatigue, Nasdaq, BHC, Anxiety, World Health Organization, Death, Patient, Enzyme, Short bowel syndrome, CEO, Infection, Simplex, Pharmaceutical industry, Vaccine, IMC-1 and IMC-2, Virios Therapeutics, Bateman Horne Center of Excellence, IMC-1 AND IMC-2, VIRIOS THERAPEUTICS, BATEMAN HORNE CENTER OF EXCELLENCE

Virios Therapeutics, Inc. is providing BHC with an unrestricted grant for an investigator-sponsored study to explore the therapeutic potential of combination antiviral therapy with Virios second development candidate, IMC-2.

Key Points: 
  • Virios Therapeutics, Inc. is providing BHC with an unrestricted grant for an investigator-sponsored study to explore the therapeutic potential of combination antiviral therapy with Virios second development candidate, IMC-2.
  • The study will evaluate changes in common Long COVID symptoms such as fatigue, sleep, attention, pain, autonomic function and anxiety.
  • Virios lead antiviral development candidate, orally administered IMC-1, is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir and celecoxib.
  • Virios Therapeutics, Inc. is providing BHC with an unrestricted grant to explore the therapeutic potential of combination antiviral therapy with the Companys second development candidate, IMC-2, in managing the fatigue, sleep, attention, pain, autonomic function and anxiety associated with Long COVID.

Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia

Retrieved on: 
Wednesday, December 1, 2021
FDA, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Patient, Security (finance), Trial of the century, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CEO, Short bowel syndrome, Annual report, Private Securities Litigation Reform Act, HSV-1, Company, Forward-looking statement, Population, FM, Irritable bowel syndrome, Celecoxib, Functional somatic syndrome, U.S. Securities and Exchange Commission, Chronic pain, Conditional sentence, Physician, Fibromyalgia, Nasdaq, DNA, US, Chronic fatigue syndrome, FDA, Simplex, Therapy, Enzyme, Famciclovir, Food, Fatigue, IBS, Lists of diseases, Pharmaceutical industry, IMC-1, Virios Therapeutics, IMC-1, VIRIOS THERAPEUTICS

The FORTRESS study builds on the statistically significant results from the Companys previously completed Phase 2a FM clinical study.

Key Points: 
  • The FORTRESS study builds on the statistically significant results from the Companys previously completed Phase 2a FM clinical study.
  • The 143-patient Phase 2a trial demonstrated that IMC-1 met its primary endpoint of pain reduction and was statistically better tolerated than placebo.
  • Reaching this enrollment milestone on a timely basis indicates that we are currently on track to report top line results in Q3 of 2022.
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.

Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Track” Review Designated Antiviral Therapy, Oral IMC-1

Retrieved on: 
Monday, July 26, 2021
Health, Consumer, Women, General Health, Clinical trials, Pharmaceutical, Biotechnology, Sexually transmitted diseases and infections, Medical specialties, Virology, Herpes simplex virus, Herpes simplex, Antiviral drug, Infectious diseases, Herpes simplex research, IMC-1, Virios Therapeutics, IMC-1, VIRIOS THERAPEUTICS

This trial builds on the encouraging results from the Companys previously completed IMC-1 phase 2a FM clinical study.

Key Points: 
  • This trial builds on the encouraging results from the Companys previously completed IMC-1 phase 2a FM clinical study.
  • This dual mechanism antiviral therapy is designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication.
  • The Company anticipates reporting top line results from the currently enrolling FORTRESS Phase 2b FM trial in mid-2022.
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.

Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress

Retrieved on: 
Wednesday, June 9, 2021
Health, Consumer, Women, General Health, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Clinical research, Health, Antidepressants, Clinical pharmacology, Clinical trial, Design of experiments, Placebo, IMC-1, Virios Therapeutics, IMC-1, VIRIOS THERAPEUTICS

This result is highlighted in a poster presentation at the International Association for the Study of Pain (IASP) World Congress, being held virtually June 9 - 11, 2021 and June 16 - 18, 2021.

Key Points: 
  • This result is highlighted in a poster presentation at the International Association for the Study of Pain (IASP) World Congress, being held virtually June 9 - 11, 2021 and June 16 - 18, 2021.
  • Our Phase 2a clinical trial data showed that IMC-1 treated patients had higher overall completion rates and lower rates of discontinuation due to adverse events, as compared with placebo-treated patients.
  • In this study, IMC1 demonstrated significant reductions in pain, fatigue, and other important symptoms in patients with FM.
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Medicine, Clinical medicine, Rheumatology, Fibromyalgia, Irritable bowel syndrome, IMC-1, the IMC-1 Phase 2b Clinical Trial, Virios Therapeutics, IMC-1, THE IMC-1 PHASE 2B CLINICAL TRIAL, VIRIOS THERAPEUTICS

We are excited about the FORTRESS trial as we are testing optimized doses of IMC-1, and we will be measuring patients fibromyalgia related pain on a daily basis.

Key Points: 
  • We are excited about the FORTRESS trial as we are testing optimized doses of IMC-1, and we will be measuring patients fibromyalgia related pain on a daily basis.
  • Based on industry standard fibromyalgia patient recruitment rates, we expect to complete the trial and announce top line results in mid-2022.
  • The dosing of the first patient in this Phase 2b trial marks an important milestone for Virios, as we develop new, combination antiviral therapies to improve care standards for patients suffering from chronic diseases like fibromyalgia and irritable bowel syndrome, said Greg Duncan, Chairman and Chief Executive Officer of Virios Therapeutics.
  • Virios Therapeutics is conducting FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1).

Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the EULAR European Congress of Rheumatology

Retrieved on: 
Wednesday, June 2, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Medicine, Clinical medicine, Health, Fibromyalgia, Rheumatology, Clinical research, Mind–body interventions, Placebo, IMC-1, Virios Therapeutics, IMC-1, VIRIOS THERAPEUTICS

Patients receiving IMC1 treatment reported significantly greater improvements versus placebo on the FIQR symptom items for stiffness, sleep quality, depression, and anxiety.

Key Points: 
  • Patients receiving IMC1 treatment reported significantly greater improvements versus placebo on the FIQR symptom items for stiffness, sleep quality, depression, and anxiety.
  • Improvements in patient global assessments and in fatigue assessments provide additional evidence for the beneficial effects of IMC1 on FM related symptoms.
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.
  • These trial results are suggestive that IMC-1 may represent a new and novel treatment for fibromyalgia.

Virios Therapeutics Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW)

Retrieved on: 
Monday, May 24, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, IMC-1, Virios Therapeutics, IMC-1, VIRIOS THERAPEUTICS

The data presented by Dr. Duffy comprised a tissue biopsy study jointly conducted between the University of Alabama and Virios Therapeutics, commented R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Virios Therapeutics.

Key Points: 
  • The data presented by Dr. Duffy comprised a tissue biopsy study jointly conducted between the University of Alabama and Virios Therapeutics, commented R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Virios Therapeutics.
  • This finding highlights the potential role of activated HSV-1 as a potential root cause of chronic gastrointestinal disorders.
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.
  • Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. (VIRI) undertakes no duty to update such information except as required under applicable law.